ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Challenges Use Of Avastin In UK To Treat Eye Disease

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drug maker Novartis (NVS) is challenging the use of a unlicensed cheaper medicine to treat an eye disease in the U.K. as an alternative to its drug Lucentis. "It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available," Novartis said in a statement. "It undermines the regulatory process that was introduced to safeguard patients." Novartis also said there is "emerging evidence" of potential safety concerns on the use of Avastin, or bevacizumab, to treat a neovascular form of age related macular degeneration, known as wet AMD. The BBC Tuesday said Novartis was seeking a judicial review of the policy to pay for Avastin on the publicly funded National Health Service, after the NHS in four areas in the south of England agreed last year that Avastin could be prescribed for the condition. Novartis declined to comment on whether it was seeking the review. Lucentis, Novartis' best-selling eye drug which generated $2.05 billion in sales in 2011, is recommended for use by the NHS to treat wet age-related macular degeneration. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/24/201404:30:12Novartis 1Q Profit Rises About 23%
04/24/201402:40:06Novartis 1st Quarter Profit Rises About 23%
04/24/201402:27:06Novartis First-Quarter Profit Rises About 23% -- Update
04/22/201413:06:07LONDON MARKETS: Glaxo, AstraZeneca Lead U.K. Stocks To Two-week...
04/22/201412:38:25EUROPE MARKETS: Drug Stocks Drive European Markets Higher
04/22/201412:35:06Novartis 1Q 2014 -- Forecast
04/22/201409:50:05Glaxo Exits Cancer Drugs
04/22/201409:44:35LONDON MARKETS: Glaxo, AstraZeneca Lead Gains In U.K. Stocks
04/22/201409:34:59U.S. Stock Futures Trade Flat
04/22/201408:32:05Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201405:51:23Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201404:40:14European Stocks Start Strongly After Easter Holiday
04/22/201403:16:43Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/10/201412:25:40Zurich Stocks See Gains
04/09/201408:34:24Novartis Names New Alcon, Sandoz Division Heads -- Update
04/09/201402:50:35Novartis Names New Alcon, Sandoz Division Heads
04/03/201417:12:35ADR Shares End Lower; Vodafone Shares Active
04/02/201416:55:18ADR Shares End Higher; Noah Education Shares Active
03/31/201417:16:48ADR Shares End Higher; ING, Novartis Shares Active
03/31/201412:29:09EUROPE MARKETS: European Stocks End Mixed On Inflation Jitters

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad